Weber, Wolfgang A.

Selected publications

¹⁸ F-FDG PET/CT for monitoring of ipilimumab therapy in patients with metastatic melanoma. Journal of Nuclear Medicine. 2019 Academic Article GET IT
Times cited: 6
EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. Cancer Discovery. 2019 Academic Article GET IT
Times cited: 13
Reproducibility and repeatability of semiquantitative¹⁸F-Fluorodihydrotestosterone uptake metrics in castration-resistant prostate cancer metastases: A prospective multicenter study. Journal of Nuclear Medicine. 2018 Academic Article GET IT
Times cited: 5
Direct imaging of drug distribution and target engagement of the PARP inhibitor rucaparib. Journal of Nuclear Medicine. 2018 Academic Article GET IT
Times cited: 3
PARP-1-targeted radiotherapy in mouse models of glioblastoma. Journal of Nuclear Medicine. 2018 Academic Article GET IT
Times cited: 3
Positron emission tomography/computed tomography-based assessments of androgenreceptor expression and glycolytic activity as a prognostic biomarker for metastatic castration-resistant prostate cancer. JAMA oncology. 2018 Academic Article GET IT
Times cited: 18
Target engagement imaging of PARP inhibitors in small-cell lung cancer. Nature Communications. 2018 Academic Article GET IT
Times cited: 11
Biodistribution and radiation dose estimates for ⁶⁸Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging. 2018 Academic Article GET IT
Times cited: 4
Discriminating radiation injury from recurrent tumor with [¹⁸F]PARPi and amino acid PET in mouse models. EJNMMI Research. 2018 Academic Article GET IT
Times cited: 2
Targeted PET imaging strategy to differentiate malignant from inflamed lymph nodes in diffuse large B-cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America. 2017 Academic Article GET IT
Times cited: 8
Multinuclear NMR and MRI reveal an early metabolic response to mTOR inhibition in sarcoma. Cancer Research. 2017 Academic Article GET IT
Times cited: 6
Repeatability of [⁶⁸Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer. Molecular Imaging and Biology. 2017 Academic Article GET IT
Times cited: 3
Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2017 Academic Article GET IT
Times cited: 15
Biomarker-based PET imaging of diffuse intrinsic pontine glioma in mouse models. Cancer Research. 2017 Academic Article GET IT
Times cited: 7
Dual-modality imaging of prostate cancer with a fluorescent and radiogallium-labeled gastrin-releasing peptide receptor antagonist. Journal of Nuclear Medicine. 2017 Academic Article GET IT
Times cited: 13
Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1 ng/ml following prostatectomy: How much information can conventional imaging provide?. Urologic Oncology: Seminars and Original Investigations. 2016 Academic Article GET IT
Times cited: 11
Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine. Journal of Clinical Investigation. 2016 Academic Article GET IT
Times cited: 39
Molecular imaging and targeted radionuclide therapy of prostate cancer. Journal of Nuclear Medicine. 2016 Academic Article GET IT
Times cited: 5
Unilateral suppression of brown fat on FDG PET/CT in horner syndrome. Clinical Nuclear Medicine. 2016 Academic Article GET IT
Times cited: 2
The impact that number of analyzed metastatic breast cancer lesions has on response assessment by ¹⁸F-FDG PET/CT Using PERCIST. Journal of Nuclear Medicine. 2016 Academic Article GET IT
Times cited: 14
Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent. Scientific Reports. 2016 Academic Article GET IT
Times cited: 17
Gastrin-releasing peptide receptor imaging in breast cancer using the receptor antagonist ⁶⁸Ga-RM2 And PET. Theranostics. 2016 Academic Article GET IT
Times cited: 22
Molecular imaging of prostate cancer. Radiographics. 2016 Review GET IT
Times cited: 42
Optical imaging of PARP1 in response to radiation in oral squamous cell carcinoma. PLoS ONE. 2016 Academic Article GET IT
Times cited: 9
A predictive model for lymph node involvement with malignancy on PET/CT in non-small-cell lung cancer. Journal of Thoracic Oncology. 2015 Academic Article GET IT
Times cited: 8
Cerenkov luminescence imaging for radiation dose calculation of a <sup>90</sup>Y-labeled gastrin-releasing peptide receptor. Journal of Nuclear Medicine. 2015 Academic Article GET IT
Times cited: 26
Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Science Translational Medicine. 2015 Academic Article GET IT
Times cited: 119
Ratio of lymph node to primary tumor SUV on PET/CT accurately predicts nodal malignancy in non-small-cell lung cancer. Clinical Lung Cancer. 2015 Academic Article GET IT
Times cited: 11
In vivo imaging of GLP-1R with a targeted bimodal PET/fluorescence imaging agent. Bioconjugate Chemistry. 2014 Academic Article GET IT
Times cited: 30
PARPi-FL--a fluorescent PARP1 inhibitor for glioblastoma imaging. Neoplasia (United States). 2014 Academic Article GET IT
Times cited: 22
¹⁸F-labeled-bioorthogonal liposomes for in vivo targeting. Bioconjugate Chemistry. 2013 Academic Article GET IT
Times cited: 54
¹⁸F-FDG-PET/CT imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy. Clinical Cancer Research. 2012 Academic Article GET IT
Times cited: 48
FDG-PET/CT imaging predicts histopathologic treatment responses after neoadjuvant therapy in adult primary bone sarcomas. Sarcoma. 2010 Academic Article GET IT
Times cited: 24
Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign (Cancer (2010) 116, (451-458)). Cancer. 2010 Article GET IT
Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer. 2010 Academic Article GET IT
Times cited: 107
FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clinical Cancer Research. 2009 Academic Article GET IT
Times cited: 119
European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. European Journal of Cancer. 2008 Article GET IT
Times cited: 35
Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clinical Cancer Research. 2008 Academic Article GET IT
Times cited: 130
Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′-¹⁸F-fluorothymidine PET. Journal of Nuclear Medicine. 2005 Academic Article GET IT
Times cited: 97

VIVO Weill Cornell Medical College

Weber, Wolfgang A. External Author

Publications

Selected publications